General
Preferred name
WO2013110309CA127
Synonyms
compound A127 [WO2013110309] ()
P&D ID
PD047139
Tags
drug candidate
Drug indication
Discovery agent
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Compound A127 is an invention covered by patent WO2013110309 . The compound is reported as an inhibitor of the serine kinase GCN2 (gene symbol EIF2AK4) , a kinase involved in the regulation of protein synthesis via phosphorylation of the alpha subunit of eukaryotic translation initiation factor-2 (EIF2α) in response to glucose deprivation. The GCN2-EIF2α-ATF4 pathway is essential for maintaining metabolic homeostasis in tumour cells . Components of this pathway, such as GCN2, are therefore novel targets for the development of anticancer therapeutics. (GtoPdb)
Compound Sets
2
DrugMAP
DMDPN4E
Guide to Pharmacology
8169
External IDs
7
Properties
(calculated by RDKit )
Molecular Weight
408.2
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
4
cLogP
2.41
TPSA
115.8
Fraction CSP3
0.35
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data